H.C. Wainwright Upholds Buy Recommendation on uniQure Amid Regulatory Discussions on AMT-130
H.C. Wainwright reaffirmed its Buy rating on uniQure, with a $70 price target signaling significant upside potential despite regulatory hurdles. The firm's outlook follows in-depth meetings with uniQure's leadership, focusing on AMT-130 for Huntington's disease and upcoming FDA engagements. While uniQure faces financial challenges, its strong liqui…